Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data (Q30665387)

26 June 2017

0 references

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data (English)

1 reference

26 June 2017

1 reference

Philippe Gabriel Steg

1

Philippe Gabriel Steg

0 references

Jonathan Day

Jonathan R Day

10

0 references

Sergio Leonardi

Sergio Leonardi

7

0 references

Kenneth W Mahaffey

6

Kenneth W Mahaffey

1 reference

26 June 2017

17

Robert A Harrington

1 reference

26 June 2017

4

Gregg W Stone

1 reference

26 June 2017

2

Deepak L Bhatt

1 reference

26 June 2017

16

Harvey D White

1 reference

26 June 2017

3

Christian W Hamm

1 reference

26 June 2017

8

Tiepu Liu

1 reference

26 June 2017

9

Simona Skerjanec

1 reference

26 June 2017

14

Luis Gruberg

1 reference

CHAMPION PHOENIX Investigators

26 June 2017

18

CHAMPION Investigators

1 reference

26 June 2017

12

Thomas D Stuckey

1 reference

26 June 2017

C Michael Gibson

5

1 reference

26 June 2017

Robert S Iwaoka

11

1 reference

26 June 2017

Harinder S Gogia

13

1 reference

26 June 2017

William J French

15

1 reference

26 June 2017

language of work or name

English

0 references

publication date

3 September 2013

1 reference

26 June 2017

1 reference

26 June 2017

382

1 reference

26 June 2017

1981-1992

1 reference

26 June 2017

9909

1 reference

The state of periprocedural antiplatelet therapy after recent trials

26 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in plat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

1 reference

7 January 2021

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Platelet inhibition with cangrelor in patients undergoing PCI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Intravenous platelet blockade with cangrelor during PCI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Effect of platelet inhibition with cangrelor during PCI on ischemic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Universal definition of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Clinical end points in coronary stent trials: a case for standardized definitions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatmen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961615-3

7 January 2021

10.1016/S0140-6736(13)61615-3

Identifiers

DOI

1 reference

26 June 2017

1 reference